FiercePharma

SK Life Science plots 2020 launch for now-approved seizure drug Xcopri

SK Life Science has set out to transform itself into a commercial biopharma company, and with its seizure med Xcopri now armed with an FDA approval, the drugmaker is gearing up for its first-ever ...
FiercePharma

SK Life Science debuts Xcopri virtual effort for HCPs to empathize with seizure patients' experiences

SK Life Science is inviting healthcare providers to literally put themselves in the shoes of patients with seizures—well, in a virtual way. The company's immersive “Step into Their Shoes” experience, ...
Yahoo Finance

New SK Life Science, Inc. Survey Reveals Communication Gaps Between Patients and Providers That Can Impact Epilepsy Care Outcomes

The survey, Hope, Hesitancy, and Hard Truths: A Patient and Provider Perspective on Epilepsy Treatment, conducted by Wakefield Research among 500 patients living with epilepsy and 450 healthcare ...
Morningstar

SK Life Science Launches Its Second National Ad, Continuing to Lead with the Only Direct-to-Consumer Commercial for an Anti-Seizure Drug in the U.S.

"Road to Reduction" Begins Airing Today Raising Awareness of XCOPRI® (cenobamate tablets) CV and the Journey to Seizure Management for People Living with Epilepsy PARAMUS, N.J., May 19, 2025 ...